Investments
100Portfolio Exits
36Funds
1About HBM Partners
HBM BioCapital (EUR) L.P. and HBM BioCapital (USD) L.P. are private equity funds with a total committed capital of EUR 115 million. The funds are managed by HBM Partners and are focused on healthcare / life science investments in Europe and the U.S. They were launched in 2005. HBM BioCapital I has made investments in 15 private companies in the pharma, biotechnology, medical devices and diagnostics industries, seven of which have been sold or listed on a stock exchange. Larger transactions were shared with HBM BioVentures. Investors in HBM BioCapital I are HBM BioVentures, larger institutional investors and pharma entrepreneurs.
HBM Partners Headquarter Location
PO-Box 1145
Zug, CH-6301,
Switzerland
+41 43 888 7171
Latest HBM Partners News
Mar 30, 2022
Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, has closed a $100 million Series C financing round led by SoftBank Vision Fund 2, bringing the company's total financing raised to date to $213.5 million. Neuron23's Series A and B investors - Westlake Village BioPartners, Kleiner Perkins, Redmile Group, Cowen Healthcare Investments, Acorn Bioventures, HBM Partners, Perceptive Advisors, and Surveyor Capital (a Citadel company) - also participated in the Series C financing round. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
HBM Partners Investments
100 Investments
HBM Partners has made 100 investments. Their latest investment was in Neuron23 as part of their Series C on March 3, 2022.
HBM Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/30/2022 | Series C | Neuron23 | $100M | No | 2 | |
12/29/2021 | Series G | Gynesonics | $32.5M | No | ||
5/20/2021 | Series C | Numab Therapeutics | $111M | Yes | 6 | |
3/8/2021 | Series D | |||||
1/11/2021 | Series E |
Date | 3/30/2022 | 12/29/2021 | 5/20/2021 | 3/8/2021 | 1/11/2021 |
|---|---|---|---|---|---|
Round | Series C | Series G | Series C | Series D | Series E |
Company | Neuron23 | Gynesonics | Numab Therapeutics | ||
Amount | $100M | $32.5M | $111M | ||
New? | No | No | Yes | ||
Co-Investors | |||||
Sources | 2 | 6 |
HBM Partners Portfolio Exits
36 Portfolio Exits
HBM Partners has 36 portfolio exits. Their latest portfolio exit was Arena Pharmaceuticals on December 13, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/13/2021 | Acq - P2P | 5 | |||
6/29/2021 | Acquired | 2 | |||
7/24/2020 | IPO | 7 | |||
Date | 12/13/2021 | 6/29/2021 | 7/24/2020 | ||
|---|---|---|---|---|---|
Exit | Acq - P2P | Acquired | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 5 | 2 | 7 |
HBM Partners Fund History
1 Fund History
HBM Partners has 1 fund, including HBM Cobra India.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
3/5/2020 | HBM Cobra India | $48.86M | 1 |
Closing Date | 3/5/2020 |
|---|---|
Fund | HBM Cobra India |
Fund Type | |
Status | |
Amount | $48.86M |
Sources | 1 |
HBM Partners Team
3 Team Members
HBM Partners has 3 team members, including current Chief Executive Officer, Andreas Wicki.
Name | Work History | Title | Status |
|---|---|---|---|
Andreas Wicki | Chief Executive Officer | Current | |
Erwin Troxler | Chief Financial Officer | Current | |
Ulrich Geilinger | Senior Partner | Current |
Name | Andreas Wicki | Erwin Troxler | Ulrich Geilinger |
|---|---|---|---|
Work History | |||
Title | Chief Executive Officer | Chief Financial Officer | Senior Partner |
Status | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.